Outcomes in Transplant Recipients Treated with Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection

Transplantation

Volumn 100, Issue 10, 2016, Pages e74-e80

  Avery, Robin K ^a   Arav Boger, Ravit ^b   Marr, Kieren A ^a   Kraus, Edward ^b   Shoham, Shmuel ^a   Lees, Laura ^b   Trollinger, Brandon ^b   Shah, Pali ^b   Ambinder, Rich ^c   Neofytos, Dionysios ^a   Ostrander, Darin ^a   Forman, Michael ^b   Valsamakis, Alexandra ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CALCIUM; FOSCARNET; GANCICLOVIR; MAGNESIUM; PHOSPHATE; POTASSIUM; VALACICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY DYSFUNCTION; LEG CRAMP; MALAISE; MALE; MORTALITY; MOUTH ULCER; NAUSEA; NEUTROPENIA; ORGAN TRANSPLANTATION; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SOLID ORGAN TRANSPLANT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE INCONTINENCE; UROGENITAL ULCER; VIROLOGY; ADOLESCENT; ANTIVIRAL RESISTANCE; CHILD; CYTOMEGALOVIRUS INFECTIONS; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; FOSCARNET; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANT RECIPIENTS;

EID: 84982840819     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001418     Document Type: Article

References (27)

1. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645-649.
2. Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis. 2002;4:189-194.
3. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866-872.
4. Gracia-Ahufinger I, Gutierrez-Aroca J, Cordero E, et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation. 2013;95:1015-1020.
5. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis. 2002;34:1337-1341.
6. Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis. 2004;189:1355-1361.
7. Erard V, Guthrie KA, Seo S, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61:31-39.
8. Florescu DF, Abu-Elmagd K,Mercer DF, et al. An international survey of cytomegalovirus prevention and treatment practices in intestinal transplantation. Transplantation. 2014;97:78-82.
9. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010; 90:419-426.
10. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12:489-496.
11. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl JMed. 2013; 369:1227-1236.
12. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11:1079-1084.
13. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014; 370:1781-1789.
14. Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46:1455-1457.
15. Wolf DG, Shimoni A, Resnick IB, et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res. 2011;90:183-186.
16. Bacigalupo A, Boyd A, Slipper J, et al. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. Expert Rev Anti Infect Ther. 2012;10:1249-1264.
17. Reddy AJ, Zaas AK, Hanson KE, et al. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant. 2007;26:1286-1292.
18. Asakura M, Ikegame K, Yoshihara S, et al. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int J Hematol. 2010;92:351-359.
19. Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011;92:217-223.
20. da Cunha-Bang C, Kirkby N, Sonderholm M, et al. The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. Am J Transplant. 2013;13:458-466.
21. Minces LR, Nguyen MH, Mitsani D, et al. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob Agents Chemother. 2014;58:128-135.
22. Fisher CE, Knudsen JL, Guthrie KA, et al. Risk factors and outcomes associated with ganciclovir resistant cytomegalovirus infection following solid organ transplantation: a retrospective case-control study. Berlin, Germany: Poster presentation, Immunocompromised Host Society; 2014.
23. Pierce B, Richardson C, Brown J, et al. Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single center study. Philadelphia, PA: Poster presentation, Am Transplant Congress; 2015.
24. Forman M, Wilson A, Valsamakis A. Cytomegalovirus DNA quantification using an automated platform for nucleic acid extraction and real-time PCR assay setup. J Clin Microbiol. 2011;49:2703-2705.
25. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.
26. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689-712.
27. NicholsWG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867-874.